Write your message
Volume 21, Issue 6 (12-2018)                   J Arak Uni Med Sci 2018, 21(6): 7-13 | Back to browse issues page

XML Persian Abstract Print

1- Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Science, Isfahan, Iran. , simaakhavan@ymail.com
2- School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Department of Neurology, Isfahan University of Medical Science, Isfahan, Iran.
Abstract:   (715 Views)
Background and Aim: Migraine is a common disease with throbbing and unilateral quality, which is accompanied by aura symptoms such as nausea, vomiting and photophobia. The level of procalcitonin is increased in migraine, which is due to the inflammation caused by a low level of serum serotonin. This study aims to investigate the level of serum procalcitonin in patient with migraine by prescribing serotonin agonist drugs.
Materials and Methods: In this case-control study, 40 migraine patients in the center of migraine patients of al-zahra university hospital in Isfahan were selected, among which 26 patients received serotonin as a treatment while the other 14 ones were treated by drugs other than sumatriptan agonist. Then, the level of procalcitonin in these patients was calculated and analyzed.
Findings: The results of the study showed that there was a difference between of the case and control groups in the level of procalcitonin in the serum of their sample blood tests. It seems that the case group patients have a lower level of procalcitonin compared to the control group.
Conclusion: Totally, the current study indicates the effect of serotonin in reducing the level of serum procalcitonin.
Full-Text [PDF 2051 kb]   (244 Downloads)    
Type of Study: Original Atricle | Subject: Surgery
Received: 2017/10/30 | Accepted: 2018/09/30

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache: The Journal of Head and Face Pain. 2001; 41(7):646-57.
2. Goadsby P, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1988; 23(2):193-6.
3. Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. New England Journal of Medicine. 2002; 346(4):257-70.
4. Hargreaves R, Shepheard S. Pathophysiology of migraine—new insights. Canadian journal of neurological sciences. 1999; 26(3):12-9.
5. Swidan SZ, Lake AE, Saper JR. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Current pain and headache reports. 2005; 9(1):65-70.
6. Mauskop A, Fox B. What Your Doctor May Not Tell You About (TM): Migraines: The Breakthrough Program that Can Help End Your Pain: Grand Central Publishing; 2007.
7. Shevel E. The extracranial vascular theory of migraine—a great story confirmed by the facts. Headache: The Journal of Head and Face Pain. 2011; 51(3):409-17.
8. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Critical care medicine. 2008; 36(3):941-52.
9. Miyakis S, Georgakopoulos P, Kiagia M, Pefanis A, Mountokalakis TD, Papadopoulou O, et al. Serial serum procalcitonin changes in the prognosis of acute stroke. 2004.
10. Sexton PM, Christopoulos G, Christopoulos A, Nylen ES, Snider RH, Becker KL. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Critical care medicine. 2008; 36(5):1637-40.
11. Durham PL, Russo AF. New insights into the molecular actions of serotonergic antimigraine drugs. Pharmacology & therapeutics. 2002; 94(1-2):77-92.
12. Juhász G, Zsombok T, Jakab B, Nemeth J, Szolcsányi J, Bagdy G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005; 25(3):179-83.
13. Van Rossum D, HANISCH U-K, QUIRION R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neuroscience & Biobehavioral Reviews. 1997; 21(5):649-78.
14. Durham PL, Russo AF. Serotonergic repression of mitogen-activated protein kinase control of the calcitonin gene-related peptide enhancer. Molecular endocrinology. 1998; 12(7):1002-9.
15. Arvieu L, Mauborgne A, Bourgoin S, Oliver C, Feltz P, Hamon M, et al. Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord. Neuroreport. 1996; 7(12):1973-6.
16. Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. Journal of Neuroscience. 1999; 19(9):3423-9.
17. Eltorp C, Jansen-Olesen I, Hansen A. Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide. Cephalalgia. 2000; 20(9):838-44.
18. Denijn M, De Weger R, Lips C, Van Unnik J, Den Otter W. Hybridohistochemical demonstration of alternative splicing of the CALC-I gene. The American journal of pathology. 1991; 138(2):273.
19. Hamel E, Currents H. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007; 27(11):1293-300.
20. Kowalska M, Prendecki M, Kozubski W, Lianeri M, Dorszewska J. Molecular factors in migraine. Oncotarget. 2016; 7(31):50708.
21. Ferrari M, Odink J, Tapparelli C, Van Kempen G, Pennings E, Bruyn G. Serotonin metabolism in migraine. Neurology. 1989; 39(9):1239-.
22. Turan H, Horasanli B, Ugur M, Arslan H. Procalcitonin levels in migraine patients. Canadian Journal of Neurological Sciences. 2011; 38(1):124-8.
23. Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia. 2012; 32(2):140-9.